Multabody™ Platform for HIV Therapeutics
Radiant Biotherapeutics, a Toronto-based biotechnology company, is developing its Multabody™ platform, which enables multivalent, multispecific antibody targeting within a single molecule and aims to increase potency and breadth relative to traditional monoclonal antibodies. The Foundation’s investment supports development of a preclinical HIV-directed Multabody program, with the potential to improve efficacy and cost-effectiveness for use in low- and middle-income countries.
- Focus areas
- Life Sciences
- Investment type
- Direct equity
- Status
- Active
- Initial investment
- Series A
- Partnered in
- 2024
- Headquarters
- USA
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.